Navigation Links
PET/CT may improve prognosis for patients with inflammatory breast cancer
Date:2/2/2009

Reston, Va.In the largest study to date to evaluate fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) in the initial staging of inflammatory breast cancer (IBC), researchers were able to identify the precise location and extent of metastasis (spread of disease), offering the potential for a better prognosis for patients with this rare, but aggressive form of breast cancer.

"PET/CT is useful in staging IBC because it provides information on both the primary disease site as well as disease involvement throughout the rest of the body," said Homer A. Macapinlac, MD, chair and professor of nuclear medicine at the University of Texas, M. D. Anderson Cancer Center, Houston, Texas. "In addition to detecting the presence of cancer, PET/CT is able to demonstrate the biology of cancerrevealing how aggressive the disease iswhich can help physicians develop appropriate therapy approaches."

For the study, published in the February issue of The Journal of Nuclear Medicine, researchers reported findings in 41 women between the ages of 25 and 71 with unilateral primary IBC who had originally presented with swelling, some pain and skin changes, such as rash and skin discoloration. A palpable mass was not evident on physical examination in 26 patients (63 percent), which is not unusual in this form of breast cancer, and 90 percent had no symptoms of distant metastasis (disease spread beyond the breast).

Each patient underwent a whole-body FDG-PET/CT exam. The scans showed that nearly half of the patients (49 percent) had distant metastasis, and 27 percent had disease in multiple sites. Neither finding had been previously detected by conventional imaging. These results were confirmed by biopsy and supplementary imaging.

"Breast cancer is a systemic disease, not just a local one. Most imaging modalities are localized and will therefore miss the spread of disease that is frequently present by the time IBC is diagnosed," Macapinlac said. "The use of a whole-body modality such as PET/CT with its higher sensitivity, however, allows us to pinpoint metastasis in other parts of the body; for example, behind the claviclewhich can not be detected in a physical examor in the abdominal organs or pelvic lymph nodes."

IBC tends to grow more quickly and aggressively than the more common types of breast cancer. Upon diagnosis, it is already considered to be at least stage IIIB (locally advanced) and even stage IV if it has spread to distant parts of the body. Because of this, IBC has been harder to successfully treat than other types of breast cancer. Knowing the extent of the disease at the start could have a great impact on the outcome for many patients, Macapinlac added.

"With FDG-PET/CT, physicians are able to accurately determine the location of metastases early in the disease process when appropriate treatment can be administered. Furthermore, a PET/CT procedure for IBC patients may be less than or equivalent to the total cost of separately imaging multiple organs and would require a single hospital visit and decreased imaging time when compared to the time required for a battery of regional staging studies," Macapinlac said.

The researchers would like to see future studies that use PET/CT earlier in the process and also to track therapy response to determine whether or not it is succeeding.

"Knowing the extent of disease up front has great implication for prognosis," Macapinlac said. "IBC is a treatable disease. The sooner we can determine the extent, the sooner we can begin aggressive therapy."

PET provides information about how the body is functioning at the cellular level, while CT provides an anatomical rendering of the inside of the body. In an FDG-PET/CT scan, the CT first produces detailed images of the inner anatomy of the body. The patient is then injected with a small amount of a radioactive drug, which is F-18-labeled glucose, and PET is performed. Because fast-growing cancer cells feed on sugars such as glucose, PET/CT delineates areas where the glucose accumulates in the body, identifying the location of cancer cells.

According to the American Cancer Society, IBC accounts for approximately 1 to 3 percent of all breast cancers diagnosed in the United States. It tends to occur in younger women, and African-Americans appear to be at higher risk. Physicians call the disease "inflammatory breast cancer" because the affected breast displays the same symptoms that occur with inflammation. However, the symptoms of IBC are not caused by infection or injury, but by cancer cells blocking lymph vessels in the skin. Patients often do not have a breast lump, and symptoms may not show up on a mammogram. Because it doesn't look like a typical breast cancer, the disease can be harder to diagnose.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert  

Related medicine news :

1. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer
2. MRI and PET/CT can prevent unnecessary treatment of some cervical cancer patients
3. PET/CT planning beneficial for head and neck cancer patients
4. Combo PET/CT Scan Helps Spot Breast Cancers Spread
5. PET/CT brings new hope to patients with deadly form of breast cancer
6. PET/CT Brings New Hope to Patients With Deadly Form of Breast Cancer
7. 18F-DG PET/CT can highly increase the detection of colorectal cancer
8. ATi Tailored BI and Advanced Predictive Analytics Solutions Improve Marketing Response Rates
9. Vascular drug found to improve learning and memory in middle-aged rats
10. Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praegers Sensible Foods
11. Patient-Centered Medical Homes Can Improve Care, Reduce Costs; Independence Blue Cross Medical Executive Discusses Innovative PA Program With Nations Health Care Policy Makers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PET/CT may improve prognosis for patients with inflammatory breast cancer
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology: